At a recent CGD staff presentation of our work into COVID-19 vaccines, our colleagues raised a large number of interesting questions, so, we asked our colleagues to send in their questions on the COVID-19 vaccine portfolio.
CGD Policy Blogs
Today we launch an interactive tool that analyses the COVID-19 vaccine portfolio, and generates estimates about the timelines for the vaccines in the portfolio.
As the world awaits the results of COVID-19 vaccine clinical trials, we have interviewed sixteen vaccine experts from the vaccine industry, academic, and regulatory agencies. Their overall message: the time to prepare is now.
Our new paper aims to answer this question using mathematical modelling and expert interviews to: better understand the COVID-19 vaccine portfolio, and generate probabilistic estimates on timelines for approval and the manufacturing scale up.
We are developing a system of interconnected models which represent global manufacturing capability from the start of clinical trials to secondary vaccine manufacture; that is, time from first human trials to finished product ready to be shipped.
This blog outlines some of the challenges in the global supply of medicines and introduces a methodology that will enable countries to spot early challenges in supply.
Around the world COVID-19 and the policy responses to it are causing unprecedented disruptions of life and wellbeing. As scientists and governments around the world race to develop a vaccine at scale, we take a look at what a portfolio approach entails and why it is so important.